Extended adjuvant treatment of patients with HER2+ early breast cancer with neratinib: a multi-centric, prospective, non-interventional study (NIS) in Germany and Austria (ELEANOR)

Extended adjuvant treatment of patients with HER2+ early breast cancer with neratinib: a multi-centric, prospective, non-interventional study (NIS) in Germany and Austria (ELEANOR)

Bibliographic Details
Main Authors:	R. Bartsch, D. Lüftner, M. Balic, G. Rinnerthaler, C. Jackisch, V. Müller, M. Schmidt, N. Harbeck
Format:	Article
Language:	English
Published:	Elsevier 2021-04-01
Series:	Breast
Online Access:	http://www.sciencedirect.com/science/article/pii/S0960977621000916

Similar Items

P014 Interim analysis of ELEANOR (n = 200): a multi-national, prospective, non-interventional study (NIS) among patients with HER2+ and HR+ early breast cancer (eBC) treated with extended adjuvant neratinib
by: R. Bartsch, et al.
Published: (2023-03-01)

Neratinib as extended adjuvant therapy in patients with HER2-positive/HR-positive early breast cancer: German HTA-driven analyses from the ExteNET study
by: D. Lüftner, et al.
Published: (2021-04-01)

P009 A real-world prospective observational multi-national study in adult patients with breast cancer treated with extended adjuvant neratinib: NERLYFE study
by: N. Harbeck, et al.
Published: (2023-03-01)

Neratinib for HER2-positive breast cancer with an overlooked option
by: Liting Guo, et al.
Published: (2023-10-01)

Conclusion: Eleanor Roosevelt and Her Transatlantic Quest for Equality and Freedom
by: Dario Fazzi
Published: (2017-03-01)

Transcriptome analysis of neratinib treated HER2 positive cancer model vs untreated cancer unravels the molecular mechanism of action of neratinib
by: Sara Alkhezayem, et al.
Published: (2020-08-01)

Neratinib and the Role of Anti‐HER2 Therapy in Salivary Duct Carcinoma
by: Martina Napolitano, et al.
Published: (2025-01-01)

Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer
by: Iwata, Hiroji, et al.
Published: (2019)

Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness
by: Arlene Chan
Published: (2016-09-01)

Eleanor & Park /
by: Rowell, Rainbow, author
Published: (2012)

Eleanor rigby /
by: 413090 Coupland, Douglas
Published: (2005)

The Analysis of Bullying Experienced By Eleanor in Rainbow Rowell's Eleanor & Park.
by: Santosa Santosa
Published: (2022-06-01)

Peptidylarginine deiminase 3 modulates response to neratinib in HER2 positive breast cancer
by: Inés Romero-Pérez, et al.
Published: (2024-08-01)

Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
by: James J. Harding, et al.
Published: (2023-02-01)

Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer
by: Nadia Harbeck
Published: (2022-03-01)

Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer
by: N. Harbeck
Published: (2021-04-01)

Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo
by: Neil T Conlon, et al.
Published: (2024-11-01)

The story of Eleanor Roosevelt /
by: 448219 Eaton, Jeanette, et al.
Published: (1963)

Eleanor Roosevelt in Montreal
by: Greg Robinson
Published: (2018-12-01)

P006 Randomized Phase II trial evaluating three anti-diarrhoeal prophylaxis strategies in patients with HER2+/HR+ early breast cancer treated with extended adjuvant neratinib (DIANER GEICAM/2018-06)
by: S. González-Santiago, et al.
Published: (2023-03-01)

Preclinical characteristics of the irreversible pan-HER kinase inhibitor neratinib compared with lapatinib : implications for the treatment of HER2-positive and HER2-mutated breast cancer
by: Collins, Denis M., et al.
Published: (2020)

“The Trust of Spring – for Eleanor” and illustrations
by: Cavicchi, Elizabeth
Published: (2023)

“And with all she lived with casual unawareness of her value to civilization”: Close-reading Eleanor Roosevelt’s Autofabrication
by: Sara Polak
Published: (2017-03-01)

Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models
by: Arshad, M, et al.
Published: (2024)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
by: Jamunarani Veeraraghavan, et al.
Published: (2021-05-01)

Exceptional disease control with neratinib monotherapy in HER2-positive advanced breast cancer: A case report
by: Pierluigi di Mauro, et al.
Published: (2022-06-01)

Eleanor Roosevelt’s Radio Broadcasts in France
by: Anya Luscombe
Published: (2017-03-01)

Eleanor Roosevelt and Diplomacy in the Public Interest
by: Anya Luscombe, et al.
Published: (2017-03-01)

First person – Eleanor McKay
Published: (2024-06-01)

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib
by: Laurence Booth, et al.
Published: (2019-07-01)

Neratinib protects pancreatic beta cells in diabetes
by: Amin Ardestani, et al.
Published: (2019-11-01)

(Trial in progress) A real-life prospective, observational, post-authorisation safety study in adult breast cancer patients treated with neratinib in extended adjuvant in Europe: the NERLYFE study
by: R. Valenti, et al.
Published: (2021-04-01)

Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib
by: Stephanie N. Shishido, et al.
Published: (2022-02-01)

Economic evaluation of third-line neratinib plus capecitabine versus lapatinib plus capecitabine with HER2+ metastatic breast cancer
by: Lanqi Ren, et al.
Published: (2023-08-01)

The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer
by: Chilà G, et al.
Published: (2021-06-01)

PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening
by: Jangsoon Lee, et al.
Published: (2021-06-01)

Self-employment in Germany and Austria
by: Rolf Wank
Published: (2023-12-01)

Germany, Austria and dissolution of Yugoslavia
by: Vuković Slobodan V.
Published: (2001-01-01)

Profile of neratinib and its potential in the treatment of breast cancer
by: Feldinger K, et al.
Published: (2015-06-01)

Neratinib, a pan ERBB/HER inhibitor, restores sensitivity of PTEN-null, BRAFV600E melanoma to BRAF/MEK inhibition
by: Evan DuBose, et al.
Published: (2024-05-01)